Piper Jaffray cut the price target on Covidien, Ltd. COV to $52 from $57, but is keeping its Overweight rating after the company hosted an investor day.
In the research note, Piper Jaffray writes, "Revenue guidance for FY (Sept) 2011 of 6-9% bracketed the current estimates and should stabilize investor sentiment as a lowered revenue range was anticipated by some. We now expect reported FY11 revenue growth to be 7.7% (was 7.9%). We are reducing our earnings estimate slightly to reflect some pricing and utilization pressure and Fx impact. COV also stated it is now anticipating only half as much dilution from ev3 as was previously forecast ($0.12-$0.15). With P/E multiples in medtech compressing, we are lowering our PT to $52/share."
Shares of COV gained 21 cents yesterday to close at $37.90.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in